Literature DB >> 11520595

Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis; relevance to pathogenesis.

S M Akbar1, M Abe, H Murakami, K Tanimoto, T Kumagi, Y Yamashita, K Michitaka, N Horiike, M Onji.   

Abstract

The levels of macrophage migration inhibitory factor (MIF), a proinflammatory and carcinogenic cytokine, were significantly higher in the sera from patients with hepatocellular carcinoma (HCC; 25.6+/-15.3 ng/ml, n=55) and liver cirrhosis (LC; 18.9+/-10.7 ng/ml, n=26) compared with sera from patients with gastrointestinal cancer (6.8+/-7.5 ng/ml, n=29) and normal controls (5.6+/-1.2 ng/ml, n=45; P<0.01). Hepatocytes from patients with LC and HCC, but not from chronic hepatitis, expressed very high levels of MIF. A possible association between overexpression of MIF and hepatocarcinogenesis is suggested.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520595     DOI: 10.1016/s0304-3835(01)00606-1

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  17 in total

1.  Clinicopathological significance of macrophage migration inhibitory factor and its relation with p53 in gastric cancer.

Authors:  Majid Nabizadeh Marvast; Hamid Reza Sima; Kamran Ghaffarzadehgan; Ali Taghizadeh Kermani; Nona Norouzi
Journal:  J Gastrointest Cancer       Date:  2011-03

2.  Macrophage migration inhibitory factor is required for recruitment of scar-associated macrophages during liver fibrosis.

Authors:  Mark A Barnes; Megan R McMullen; Sanjoy Roychowdhury; Nabil Z Madhun; Kathryn Niese; Mitchell A Olman; Abram B Stavitsky; Richard Bucala; Laura E Nagy
Journal:  J Leukoc Biol       Date:  2014-11-14       Impact factor: 4.962

3.  Expression of macrophage migration inhibitory factor is associated with enhanced angiogenesis and advanced stage in gastric carcinomas.

Authors:  Chia-Tung Shun; Jaw-Town Lin; Shih-Pei Huang; Min-Tsan Lin; Ming-Shiang Wu
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

4.  Macrophage migration inhibitory factor stimulated by Helicobacter pylori increases proliferation of gastric epithelial cells.

Authors:  Harry Hua-Xiang Xia; Shiu Kum Lam; Annie O O Chan; Marie Chia Mi Lin; Hsiang Fu Kung; Keiji Ogura; Douglas E Berg; Benjamin Chun-Yu Wong
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

5.  Macrophage migration inhibitory factor as a potential prognostic factor in gastric cancer.

Authors:  Long-Jun He; Dan Xie; Pin-Jin Hu; Yi-Ji Liao; Hai-Xia Deng; Hsiang-Fu Kung; Sen-Lin Zhu
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

6.  The diagnostic value of macrophage migration inhibitory factor (MIF) in gastric cancer.

Authors:  Hakan Camlica; Derya Duranyildiz; Hilal Oguz; Ethem Nezih Oral; Vildan Yasasever
Journal:  Pathol Oncol Res       Date:  2008-03-18       Impact factor: 3.201

7.  Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis.

Authors:  X-X He; J Yang; Y-W Ding; W Liu; Q-Y Shen; H H-X Xia
Journal:  Gut       Date:  2006-02-17       Impact factor: 23.059

8.  Macrophage migration inhibitory factor contributes to ethanol-induced liver injury by mediating cell injury, steatohepatitis, and steatosis.

Authors:  Mark A Barnes; Megan R McMullen; Sanjoy Roychowdhury; Sorana G Pisano; Xiuli Liu; Abram B Stavitsky; Richard Bucala; Laura E Nagy
Journal:  Hepatology       Date:  2013-01-18       Impact factor: 17.425

9.  Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo.

Authors:  Qiang Zhou; Xiaocai Yan; Jill Gershan; Rimas J Orentas; Bryon D Johnson
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

10.  Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as potential biomarkers for gastric cancer.

Authors:  Y Mohri; T Mohri; W Wei; Y-J Qi; A Martin; C Miki; M Kusunoki; D G Ward; P J Johnson
Journal:  Br J Cancer       Date:  2009-06-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.